rmdopen.bmj4d
Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study
Objectives To identify serious infection (SI) risk by aetiology and site in patients with rheumatoid arthritis (RA) compared with those with non-inflammatory rheumatic and musculoskeletal diseases ...
rmdopen.bmj4d
Recognising the spectrum of scleromyositis: HEp-2 ANA patterns allow identification of a novel clinical subset with anti-SMN autoantibodies
2 Centre de Référence des Maladies Autoimmunes Rares, Hôpitaux Universitaires de Strasbourg, Strasbourg, France Objective To describe systemic sclerosis (SSc) with myopathy in patients without classic ...
rmdopen.bmj8d
Immune checkpoint molecules performance in ANCA vasculitis
Objective The PD-1 axis promotes protection against autoimmunity. Immune checkpoint (IC) molecules performance in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) remains unknown. This ...
rmdopen.bmj10d
Impact of ultrasound limitation to assess aortitis in patients with giant cell arteritis: comparative study with FDG-PET/CT
Objective To determine the impact of ultrasound (US) intrinsic limitation to assess aortitis versus FDG-PET/CT in patients with US-proven giant cell arteritis (GCA) and to identify factors associated ...
rmdopen.bmj10d
Lymph nodes as gatekeepers of autoimmune diseases
3 Amsterdam Institute for Immunology and Infectious diseases, Amsterdam, The Netherlands 4 Amsterdam Rheumatology and Immunology Centre (ARC), Amsterdam, The Netherlands Secondary lymphoid organs such ...
rmdopen.bmj10d
CAR T cells for treating autoimmune diseases
Autoimmune disorders occur when immune cells go wrong and attack the body’s own tissues. Currently, autoimmune disorders are largely treated by broad immunosuppressive agents and blocking antibodies, ...
rmdopen.bmj10d
Comorbidity management in spondyloarthritis
Comorbidities are defined as coexistent clinical disorders that appear as a consequence of persistent inflammatory activity and/or treatment. Comorbidities in spondyloarthritis (SpA) are frequent, ...
rmdopen.bmj10d
Metabolomic profiles, polygenic risk scores and risk of rheumatoid arthritis: a population-based cohort study in the UK Biobank
Objective To investigate the relationship between metabolomic profiles, genome-wide polygenic risk scores (PRSs) and risk of rheumatoid arthritis (RA). Methods 143 nuclear magnetic resonance-based ...
rmdopen.bmj10d
Impact of hyperuricaemia on patients with psoriatic arthritis treated with secukinumab in the FUTURE 2–5 and MAXIMISE studies
Objectives Patients with psoriatic arthritis (PsA) are at a significantly increased risk of hyperuricaemia and development of gout, and those with hyperuricaemia have been found to respond poorly to ...
rmdopen.bmj10d
Atlas of the OMERACT Heel Enthesitis MRI Scoring System (HEMRIS)
Objective Assessment of enthesitis, a key feature in spondyloarthritis (SpA) and psoriatic arthritis (PsA), using objective and sensitive methods is pivotal in clinical trials. MRI allows detection of ...
rmdopen.bmj10d
Effect of celastrol on bone structure and mechanics in arthritic rats
Objective Rheumatoid arthritis (RA) is characterised by chronic inflammation leading to articular bone and cartilage damage. Despite recent progress in RA management, adverse effects, lack of efficacy ...
rmdopen.bmj10d
Antibodies against citrullinated proteins of IgA isotype are associated with progression to rheumatoid arthritis in individuals at-risk
Objective Events triggering disease outbreak in individuals at-risk for rheumatoid arthritis (RA at-risk) remain unclear, and the role of the various anticitrullinated protein antibody (ACPA) isotypes ...